• Explore /
  • Poster
  • / Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder.

Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder.

Abstract Poster

Authors

null

Jonathan Lawrence Wright

University of Washington, School of Medicine, Seattle, WA

Jonathan Lawrence Wright , Franklin Lee , William Proctor Harris , Heather H. Cheng , Song Zhao , Thomas Champion , John L. Gore , James Dean , James Dean , Michael P Porter , Evan Y. Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancer

Sub Track

Urothelial Carcinoma

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 267)

DOI

10.1200/jco.2013.31.6_suppl.267

Abstract #

267

Poster Bd #

F14

Abstract Disclosures

Similar Posters

First Author: Sarah P. Psutka

First Author: Srikala S. Sridhar

First Author: Benjamin Miron

First Author: Hiroshi Kitamura